Three Livesaving Developments Pioneered Locally

Including the first new drug approved by the FDA for Hodgkin’s lymphoma in more than 30 years.
FROM THE PRINT EDITION |
 
 

Three Eastside tech firms have pioneered lifesaving new devices and treatments in the past year. Redmond’s Mobisante has created a MOBILE ULTRASOUND IMAGING DEVICE—the MobiUS SP1 ultrasound system—that is the first smartphone-based diagnostic device to be cleared by the FDA. The device, released last October, fits into a pocket and can be charged anywhere, making it ideal for disaster relief organizations. It is also affordable and easy to use, reducing the time required to diagnose and treat patients, as does Physio-Control, Inc.’s new portable, dedicated ELECTROCARDIOGRAM DEVICE for basic-life support teams. Launched by the Redmond company last August, the ReadyLink 12-Lead ECG device is a small, lightweight tool that can acquire and transmit a patient’s ECG to hospital teams via cloud-based data technology. Also in August, Bothell company Seattle Genetics, Inc. earned FDA approval for the first in a new class of CANCER DRUGS. Adcetris is designed to target and kill cancer cells in patients with Hodgkin’s lymphoma (HL)—the first new drug approved by the FDA for HL in more than 30 years.

RELATED CONTENT

Stories by Sally James, Amelia Apfel, Sheila Cain, Elsy Pawelak Niki Stojnic
For 15 years, we have asked Seattle-area doctors this question: To whom would you send a loved one for medical care?

Today, we launch Seattle magazine’s 13th annual Top Doctors survey (seattlemag.com/topdocssurvey).

The numbers are staggering: An estimated 3.8 million sport- and recreation-related concussions occur every year across the country, according to the Centers for Disease Control and Prevention.

Multiple sclerosis is more prevalent in the Northwest than almost anywhere else on earth, for reasons that are largely unknown, according to the National Multiple Sclerosis Society—more than 12,000 people in the Northwest, Montana